全文获取类型
收费全文 | 2048篇 |
免费 | 613篇 |
专业分类
各国政治 | 46篇 |
工人农民 | 222篇 |
世界政治 | 59篇 |
外交国际关系 | 178篇 |
法律 | 1405篇 |
中国共产党 | 15篇 |
中国政治 | 353篇 |
政治理论 | 114篇 |
综合类 | 269篇 |
出版年
2023年 | 15篇 |
2022年 | 54篇 |
2021年 | 29篇 |
2020年 | 38篇 |
2019年 | 57篇 |
2018年 | 45篇 |
2017年 | 17篇 |
2016年 | 15篇 |
2015年 | 20篇 |
2014年 | 20篇 |
2013年 | 103篇 |
2012年 | 177篇 |
2011年 | 184篇 |
2010年 | 163篇 |
2009年 | 237篇 |
2008年 | 187篇 |
2007年 | 101篇 |
2006年 | 125篇 |
2005年 | 90篇 |
2004年 | 103篇 |
2003年 | 140篇 |
2002年 | 124篇 |
2001年 | 96篇 |
2000年 | 32篇 |
1999年 | 86篇 |
1998年 | 19篇 |
1997年 | 19篇 |
1996年 | 36篇 |
1995年 | 22篇 |
1994年 | 28篇 |
1993年 | 26篇 |
1992年 | 24篇 |
1991年 | 32篇 |
1990年 | 30篇 |
1989年 | 40篇 |
1988年 | 20篇 |
1987年 | 19篇 |
1986年 | 24篇 |
1985年 | 9篇 |
1984年 | 12篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 11篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1974年 | 2篇 |
1973年 | 3篇 |
排序方式: 共有2661条查询结果,搜索用时 31 毫秒
151.
劳动幸福是一种客观状态,对劳动幸福观测维度的测量有助于有针对性地提高劳动幸福程度。劳动幸福可以从四个观测维度进行测量,分别是劳动发展维度、劳动解放维度、劳动尊严维度以及劳动基础条件维度。这四个维度相互联系、互为因果,共同促进劳动幸福程度的提高。根据这样的理论建构,研究设计了"劳动幸福问卷”,对来自全国的样本进行了网络在线调查。分析结果显示,劳动幸福四维度之间具有正相关关系,符合本研究的理论建构。这说明“劳动幸福问卷”在总体上是可用的,是一个可靠和可信的研究工具。 相似文献
152.
153.
The Food and Drug Administration (FDA) is classifying the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection systems into class II (special controls). The special control that will apply to the device is the guidance document entitled "Class II Special Controls Guidance Document: CFTR Gene Mutation Detection Systems." The agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document that will serve as the special control for the device. 相似文献
154.
We are adding reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments to the list of HHS select agents and toxins. We are taking this action for several reasons. First the pandemic influenza virus of 1918-19 killed up to 50 million people worldwide, including an estimated 675,000 deaths in the United States. Also, the complete coding sequence for the 1918 pandemic influenza A H1N1 virus was recently identified, which will make it possible for those with knowledge of reverse genetics to reconstruct this virus. In addition, the first published study on a reconstructed 1918 pandemic influenza virus demonstrated the high virulence of this virus in cell culture, embryonated eggs, and in mice relative to other human influenza viruses. Therefore, we have determined that the reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments have the potential to pose a severe threat to public health and safety. 相似文献
155.
The Food and Drug Administration (FDA) is issuing a final regulation that confirms the interim final rule entitled "Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002" (68 FR 58894, October 10, 2003 (interim final rule) as corrected by a technical amendment (69 FR 29428, May 24, 2004), and responds to comments submitted in response to the request for comments in the interim final rule. This final rule affirms the interim final rule's requirement that domestic and foreign facilities that manufacture/process, pack, or hold food for human or animal consumption in the United States be registered with FDA by December 12, 2003. The interim final rule implemented the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (the Bioterrorism Act), which requires domestic and foreign facilities to be registered with FDA by December 12, 2003. This final rule does not make any changes to the regulatory requirements established by the interim final rule. 相似文献
156.
The Food and Drug Administration (FDA) is issuing a final rule to amend the Federal performance standard for diagnostic x-ray systems and their major components (the performance standard). The agency is taking this action to update the performance standard to account for changes in technology and use of radiographic and fluoroscopic x-ray systems and to fully utilize the International System of Units to describe radiation-related quantities and their units when used in the performance standard. For clarity and ease of understanding, FDA is republishing the complete contents, as amended, of three sections of the performance standard regulations and is amending a fourth section without republishing it in its entirety. This action is being taken under the Federal Food, Drug, and Cosmetic Act (the act), as amended by the Safe Medical Devices Act of 1990 (SMDA). 相似文献
157.
The Food and Drug Administration (FDA) is amending its bottled water quality standard regulations by revising the existing allowable level for the contaminant arsenic. As a consequence, bottled water manufacturers are required to monitor their finished bottled water products for arsenic at least once each year under the current good manufacturing practice (CGMP) regulations for bottled water. Bottled water manufacturers are also required to monitor their source water for arsenic as often as necessary, but at least once every year unless they meet the criteria for the source water monitoring exemptions under the CGMP regulations. This final rule will ensure that the minimum quality of bottled water, as affected by arsenic, remains comparable with the quality of public drinking water that meets the Environmental Protection Agency's (EPA's) standards. 相似文献
158.
The Food and Drug Administration (FDA) is classifying the assisted reproduction laser system into class II (special controls). The special control that will apply to the device is the guidance document entitled "Class II Special Controls Guidance Document: Assisted Reproduction Laser Systems." The agency is classifying this device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is publishing a notice of availability of the guidance document that is the special control for this device. 相似文献
159.
The Food and Drug Administration (FDA) is requiring human cell, tissue, and cellular and tissue-based product (HCT/P) establishments to follow current good tissue practice (CGTP), which governs the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps; recordkeeping; and the establishment of a quality program. The agency is also issuing new regulations pertaining to labeling, reporting, inspections, and enforcement that will apply to manufacturers of those HCT/Ps regulated solely under the authority of the Public Health Service Act (PHS Act), and not as drugs, devices, and/or biological products. The agency's actions are intended to improve protection of the public health while keeping regulatory burden to a minimum, which in turn would encourage significant innovation. 相似文献
160.
The Food and Drug Administration (FDA) is amending the general labeling provisions for over-the-counter (OTC) drug products to require that the labeling of all OTC drug products intended for oral ingestion include: The calcium content per dosage unit when the product contains 20 milligrams (mg) or more per single dose; a warning statement that persons with kidney stones and persons on a calcium-restricted diet should ask a doctor before using when the product contains more than 3.2 grams (g) of calcium in the labeled maximum daily dose; the magnesium content per dosage unit when the product contains 8 mg or more per single dose; a warning statement that persons with kidney disease and persons on a magnesium-restricted diet should ask a doctor before using if the product contains more than 600 mg magnesium in the labeled maximum daily dose; the potassium content per dosage unit when the product contains 5 mg or more per single dose; and a warning statement that persons with kidney disease and persons on a potassium restricted diet should ask a doctor before using if the product contains more than 975 mg potassium in the labeled maximum daily dose. FDA is issuing this final rule in order to provide uniform calcium, magnesium, and potassium content and warning labeling for all OTC drug products intended for oral ingestion whether marketed under an OTC drug monograph, the ongoing OTC drug review, a new drug application (NDA) or abbreviated new drug application (ANDA), or no application. 相似文献